Analyst Ratings Overview: In the past three months, 12 analysts have provided mixed ratings for Humana, with a total of 10 being indifferent and only 2 somewhat bullish.
Price Target Insights: Analysts have set an average price target of $284.17 for Humana, which is a decline from the previous target of $296.58, with estimates ranging from a low of $260.00 to a high of $344.00.
Financial Performance Indicators: Humana's financial metrics show challenges, including a net margin of 1.68%, return on equity (ROE) of 3.03%, and return on assets (ROA) of 1.08%, all below industry averages.
Market Positioning: As one of the largest private health insurers in the U.S., Humana focuses on government-sponsored programs, but its market capitalization and revenue growth are below industry standards, indicating potential growth challenges.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy HUM?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Wall Street analysts forecast HUM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HUM is 290.39 USD with a low forecast of 231.00 USD and a high forecast of 344.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
19 Analyst Rating
Wall Street analysts forecast HUM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HUM is 290.39 USD with a low forecast of 231.00 USD and a high forecast of 344.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Buy
12 Hold
1 Sell
Moderate Buy
Current: 196.670
Low
231.00
Averages
290.39
High
344.00
Current: 196.670
Low
231.00
Averages
290.39
High
344.00
Wells Fargo
Overweight -> Equal Weight
downgrade
$290
2026-01-07
Reason
Wells Fargo
Price Target
$290
AI Analysis
2026-01-07
downgrade
Overweight -> Equal Weight
Reason
Wells Fargo downgraded Humana to Equal Weight from Overweight with a $290 price target.
Wells Fargo
Stephen Baxter
Overweight -> Equal Weight
downgrade
$290
2026-01-07
Reason
Wells Fargo
Stephen Baxter
Price Target
$290
2026-01-07
downgrade
Overweight -> Equal Weight
Reason
As previously reported, Wells Fargo analyst Stephen Baxter downgraded Humana to Equal Weight from Overweight with a $290 price target. For managed care organizations, the firm is most constructive on Medicare Advantage with uncertainty high for Medicaid/Exchanges. Wells sees a more difficult backdrop for hospitals in 2026 as post-COVID tailwinds wane and legislative risks near. Distributor debate remains revisions vs. multiples. Regarding Humana, the firm is more cautious on achievability of the company's margin objective in 2026 given lack of benefit cuts.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for HUM
Unlock Now
About HUM
Humana Inc. provides Humana insurance services and CenterWell health care services. The Company's segments include Insurance and CenterWell. The Insurance segment consists of Medicare benefits, marketed to individuals or directly via group Medicare accounts, as well as its contract with CMS to administer the Limited Income Newly Eligible Transition (LI-NET) prescription drug plan program and contracts with various states to provide Medicaid, dual eligible demonstration, and Long-Term Support Services benefits. This segment also includes products consisting of employer group commercial fully-insured medical and specialty health insurance benefits marketed to individuals and employer groups. The CenterWell segment includes its pharmacy, primary care, and home solutions operations. The segment also includes its strategic partnerships with WCAS to develop and operate senior-focused, payor-agnostic, primary care centers, as well as its minority ownership interest in hospice operations.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Top and Bottom S&P 500 Stocks of January: No Surprises.
3 hours agoBarron's
Market Reactions: January has presented various challenges and opportunities for investors, prompting significant analysis and reflection on market trends.
Economic Indicators: Key economic indicators released this month have influenced investor sentiment and decision-making processes.
Continue Reading
The Stock Market Faces Numerous Questions with Few Answers
4 hours agoBarron's
Big Tech's Influence: Big Tech companies are experiencing a resurgence, but this has not led to a clear direction in the stock market.
Market Uncertainty: The current market conditions suggest that this lack of direction is likely to persist in the near future.
Continue Reading
Sigh Up to Get Intellectia Insights
What are the key allegations in the Humana shareholder lawsuit?
Why is the $260 strike put option significant for Humana investors?
How might the lawsuit impact Humana's stock performance in the future?
Will Amgen's high call option volume lead to a price increase?
What does the trading volume data suggest about market sentiment for Humana?
